Olivier Bouché

23PUBLICATIONS
182CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methodsPeripheral nervous systemCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jun 08, 2026
Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors.

|Feb 11, 2026
Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment.

Valérie Boige, Olivier Bouché, Claire Mulot

|Dec 04, 2025
Reply to: "FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies," "Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?," and "Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN".

Michel Ducreux, Matthieu Texier, Olivier Bouche

|Nov 07, 2025
Methodological approach to optimize a step-by-step deterministic linkage of SNDS data with a clinical database (FREGAT) of gastric/gastroesophageal junction adenocarcinoma in France: Pitfalls and learnings.

Magali Laborey, Audrey Lajoinie, Jonatan Freilich

|Nov 04, 2025
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.

Pascal Hammel, Jean-Philippe Metges, Teresa Macarulla Mercade

|May 16, 2025
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.

Michel Ducreux, Romain Desgrippes, Yves Rinaldi

Pageof 4

Frequent Collaborators

4 joint publications

Marine Perrier

3 joint publications

Jean-Baptiste Bachet

3 joint publications

Thierry Lecomte

3 joint publications

Christelle de la Fouchardiere